Both in Pharmaceuticals
Royalty Pharma vs Insmed
Over the past year RPRX returned +79.0% and INSM returned −40.6%; their daily moves had a correlation of 0.19.
RPRX +79.0% INSM −40.6%Growth of $1, one year, split-adjusted
| Metric | RPRX | INSM |
|---|---|---|
| Price | $67.18 | $112.58 |
| Market cap | $29.91B | $24.70B |
| Today | +1.90% | +0.89% |
| 1 month | +16.6% | +3.7% |
| 6 months | +35.8% | −15.5% |
| Year to date | +73.9% | −35.3% |
| 1 year | +83.2% | −32.6% |
| Revenue growth (YoY) | +16.5% | +268.4% |
| Gross margin | 100.0% | 85.1% |
| Net margin | 2.7% | −19.1% |
| P/E (TTM) | 36.7× | — |
| Price / sales | 11.8× | 16.3× |
| Net cash | -$8.23B | $569.9M |
| Dividend yield | 1.40% | — |
| Volatility (60d) | 24.9% | 46.7% |
| Short % of float | 2.9% | 6.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).